These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38796665)

  • 1. A journey through the history of PEGylated drug delivery nanocarriers.
    López-Estevez AM; Gref R; Alonso MJ
    Drug Deliv Transl Res; 2024 Aug; 14(8):2026-2031. PubMed ID: 38796665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated nanocarriers for systemic delivery.
    Jain NK; Nahar M
    Methods Mol Biol; 2010; 624():221-34. PubMed ID: 20217599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEGylated nanocarriers: A promising tool for targeted delivery to the brain.
    Gajbhiye KR; Pawar A; Mahadik KR; Gajbhiye V
    Colloids Surf B Biointerfaces; 2020 Mar; 187():110770. PubMed ID: 31926790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of PEGylated Polymer Nanoparticles with the Biophysical Function of Lung Surfactant.
    Beck-Broichsitter M
    Langmuir; 2018 Jan; 34(1):540-545. PubMed ID: 29220196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
    Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
    Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylated nanomedicines: recent progress and remaining concerns.
    Vllasaliu D; Fowler R; Stolnik S
    Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery.
    Fang Y; Xue J; Gao S; Lu A; Yang D; Jiang H; He Y; Shi K
    Drug Deliv; 2017 Dec; 24(sup1):22-32. PubMed ID: 29069920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of fluorinated stealth poly(ε-caprolactone) nanocarriers.
    Bona BL; Lagarrigue P; Chirizzi C; Espinoza MIM; Pipino C; Metrangolo P; Cellesi F; Baldelli Bombelli F
    Colloids Surf B Biointerfaces; 2024 Feb; 234():113730. PubMed ID: 38176337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the role of sucrose in PLGA-PEG nanocarrier for potential intranasal delivery.
    Bonaccorso A; Musumeci T; Carbone C; Vicari L; Lauro MR; Puglisi G
    Pharm Dev Technol; 2018 Mar; 23(3):265-274. PubMed ID: 28128676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Well-Characterized PEG-Coated Nanoparticles for Elucidating Biological Barriers to Drug Delivery.
    Yang Q; Lai SK
    Methods Mol Biol; 2017; 1530():125-137. PubMed ID: 28150200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery.
    Mozar FS; Chowdhury EH
    Curr Pharm Des; 2018; 24(28):3283-3296. PubMed ID: 30062957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of PEGylation patterns on the in vivo biodistribution of mixed shell micelles.
    Gao H; Liu J; Yang C; Cheng T; Chu L; Xu H; Meng A; Fan S; Shi L; Liu J
    Int J Nanomedicine; 2013; 8():4229-46. PubMed ID: 24235825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Photoinduced PEG deshielding from ROS-sensitive linkage-bridged block copolymer-based nanocarriers for on-demand drug delivery.
    Li J; Sun C; Tao W; Cao Z; Qian H; Yang X; Wang J
    Biomaterials; 2018 Jul; 170():147-155. PubMed ID: 29674231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DSPE-PEG: a distinctive component in drug delivery system.
    Che J; Okeke CI; Hu ZB; Xu J
    Curr Pharm Des; 2015; 21(12):1598-605. PubMed ID: 25594410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEGylated hyperbranched polyphosphoester based nanocarriers for redox-responsive delivery of doxorubicin.
    Chen C; Zheng P; Cao Z; Ma Y; Li J; Qian H; Tao W; Yang X
    Biomater Sci; 2016 Mar; 4(3):412-7. PubMed ID: 26626655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
    Suk JS; Xu Q; Kim N; Hanes J; Ensign LM
    Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):28-51. PubMed ID: 26456916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
    Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
    Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PEGylation of model drug carriers enhances phagocytosis by primary human neutrophils.
    Kelley WJ; Fromen CA; Lopez-Cazares G; Eniola-Adefeso O
    Acta Biomater; 2018 Oct; 79():283-293. PubMed ID: 30195083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated blood clearance phenomenon upon cross-administration of PEGylated nanocarriers in beagle dogs.
    Wang C; Cheng X; Su Y; Pei Y; Song Y; Jiao J; Huang Z; Ma Y; Dong Y; Yao Y; Fan J; Ta H; Liu X; Xu H; Deng Y
    Int J Nanomedicine; 2015; 10():3533-45. PubMed ID: 25999716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.